Scarica l'app Stockscreener
7.60
52.00%
2.60
Precedente Chiudi:
$5.00
Aprire:
$5.03
Volume 24 ore:
3.87M
Relative Volume:
15.58
Capitalizzazione di mercato:
$165.80M
Reddito:
-
Utile/perdita netta:
$-69.87M
Rapporto P/E:
-2.3684
EPS:
-3.2089
Flusso di cassa netto:
$-61.75M
1 W Prestazione:
+33.33%
1M Prestazione:
+118.39%
6M Prestazione:
-46.74%
1 anno Prestazione:
-39.68%
Intervallo 1D:
$5.03
$7.9244
Intervallo di 1 settimana:
$4.66
$7.9244
Portata 52W:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Nome
Aardvark Therapeutics Inc
Settore
Industria
Telefono
(858) 225-7696
Indirizzo
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
7.60 | 165.80M | 0 | -69.87M | -61.75M | -3.2089 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | Downgrade | Stifel | Buy → Hold |
| 2026-01-28 | Iniziato | B. Riley Securities | Buy |
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-12 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Raymond James | Strong Buy |
| 2025-11-07 | Iniziato | BTIG Research | Buy |
| 2025-09-29 | Iniziato | Stifel | Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Iniziato | BofA Securities | Buy |
| 2025-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Iniziato | Morgan Stanley | Overweight |
| 2025-03-10 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie
What's going on with Aardvark Therapeutics stock on Wednesday? - MSN
[DEF 14A] Aardvark Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Aardvark Therapeutics (AARD) Cantor Global Healthcare Conference 2025 Summary - Quartr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - AOL.com
Aardvark Therapeutics, Inc. Common Stock (NASDAQ: AARD) Stock Price, News & Analysis - Kalkine
AARD Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Navigates DevelopmentNet Profit Margin - dars.gov.et
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2000 Dynamic Index - marketscreener.com
Aardvark Therapeutics (NASDAQ: AARD) asks shareholders to reprice 2.8M options - Stock Titan
Aardvark Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 3000E Index - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2500 Index - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2000 Index - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 3000 Value Benchmark - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 2500 Value Benchmark - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Aardvark Therapeutics (AARD) Retreats 5.3% as Shares Test Key Support LevelsDouble EMA - dars.gov.et
Aardvark Therapeutics, Inc. Actuals & Estimates (NASDAQ:AARD) - TradingView
Aardvark Therapeutics, Inc. Actuals & Estimates (BOATS:AARD) - TradingView
Aardvark Therapeutics Company Profile & Introduction - Moomoo
AARD Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Aardvark Therapeutics, Inc. – NASDAQ:AARD - TradingView
Price to earnings forward of Aardvark Therapeutics, Inc. – NASDAQ:AARD - TradingView
Price to book forward of Aardvark Therapeutics, Inc. – NASDAQ:AARD - TradingView
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS - PR Newswire
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai - Bitget
Aardvark Therapeutics Leads The Charge With 2 Other Noteworthy Penny Stocks - simplywall.st
Aardvark Therapeutics Inc (AARD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aardvark Therapeutics Inc. (AARD) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Season Outlook - dars.gov.et
Aardvark Therapeutics (AARD) Gains 1.57% Amid Consolidation Near SupportTICK Divergence - dars.gov.et
Aardvark Therapeutics Inc (AARD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aardvark Therapeutics Inc (AARD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aardvark Therapeutics Inc (AARD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aardvark Therapeutics Inc (AARD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aardvark Therapeutics Inc (AARD) Institutional Confidence - TradingKey
Aardvark Therapeutics Inc (AARD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aardvark Therapeutics Inc (AARD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aardvark Therapeutics Inc (AARD) Valuation: PE, PB & Fair Value Analysis - TradingKey
AARD Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Preview - newsline.com
Aardvark Therapeutics Inc. (AARD) Gains 7% as Stock Approaches Resistance LevelRisk Reward Setups - newsline.com
Aardvark Therapeutics Implements Executive Retention Bonus Agreements - TipRanks
Executive retention bonuses outlined at Aardvark Therapeutics (NASDAQ: AARD) - Stock Titan
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc.AARD - FinancialContent
Aardvark Therapeutics Insiders Lose Out As Stock Sinks To US$3.59 - simplywall.st
Aardvark Therapeutics (AARD) Slips 2.45% as Stock Tests Key Support at $3.41Elliott Wave Entry - newsline.com
Aardvark Therapeutics (AARD) Declines Over 4% as Stock Tests Key Support LevelsVolatility Skew - newsline.com
Aardvark Therapeutics Inc Azioni (AARD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aardvark Therapeutics Inc Azioni (AARD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):